spacer
The Healthcare Sales & Marketing Network celebrates 25 years serving the medical sales & marketing community.Connecting Medical Independent Sales Reps and Distributors with Manufacturers and New Product LinesConnecting Medical Independent Sales Reps and Distributors with Manufacturers and New Product Lines

Searching News Database:  ipilimumab 

 HSMN NewsFeed - 1 Sep 2020
Blueprint Medicines Strengthens Leadership with Appointment of Fouad Namouni, M.D., as President, Research & Development
Biopharmaceuticals Personnel
 HSMN NewsFeed - 5 Nov 2019
Regeneron Provides Updates on Phase 3 Libtayo(R) (cemiplimab) Development Program in Advanced Non-small Cell Lung Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 27 Aug 2019
PIONYR Immunotherapeutics Announces Key Leadership Team Addition and Clinical Candidates Targeting Tumor-Associated Macrophages
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 1 Aug 2019
Nektar Therapeutics and Bristol-Myers Squibb Announce U.S. FDA Breakthrough Therapy Designation for Bempegaldesleukin (NKTR-214) in Combination with Opdivo(R) (nivolumab) for the Treatment of Patients with Untreated Advanced Melanoma
Biopharmaceuticals Oncology
 HSMN NewsFeed - 6 May 2019
Portage Announces Change of CEO
Biopharmaceuticals Personnel
 HSMN NewsFeed - 28 Aug 2018
OncoSec Appoints Alain Algazi, MD, as Clinical Strategic Advisor
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 9 Jul 2018
Polaris Announces Drs. James Allison and Padmanee Sharma Joining its Scientific Advisory Board
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 6 Jun 2018
Partner Therapeutics (PTx) Announces US FDA Approval of Leukine(R) (sargramostim) for the Treatment of Acute Radiation Syndrome
Biopharmaceuticals FDA
 HSMN NewsFeed - 8 Mar 2018
Infinity Pharmaceuticals Announces Additions to Board of Directors and Clinical Leadership Team and Establishes Scientific Advisory Board
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 1 Feb 2018
Partner Therapeutics (PTx) Acquires Leukine(R) from Sanofi
Biopharmaceuticals Oncology Acquisitions
 HSMN NewsFeed - 20 Sep 2017
Arvinas Appoints Dr. John Houston as President and Chief Executive Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 30 May 2017
Array BioPharma and Bristol-Myers Squibb Announce Strategic Collaboration
Biopharmaceuticals Oncology
 HSMN NewsFeed - 20 Jan 2017
Bristol-Myers Squibb Provides Regulatory Update in First-line Lung Cancer
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 11 Nov 2016
Bristol-Myers Squibb’s Opdivo(R) (nivolumab) is the First Immuno-Oncology Treatment to Receive FDA Approval Based on Overall Survival in Head and Neck Cancer
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 14 Oct 2016
Bristol-Myers Squibb Receives Positive CHMP Opinion for Opdivo (nivolumab) for the Treatment of Adult Patients With Relapsed or Refractory Classical Hodgkin Lymphoma After Autologous Stem Cell Transplant and Treatment With Brentuximab Vedotin
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 30 Mar 2016
Curis Announces Expansion of Executive Team
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 10 Dec 2015
Lilly and Merck Expand Immuno-Oncology Collaboration Adding Abemaciclib and KEYTRUDA(R) Combination Trial
Biopharmaceuticals Oncology
 HSMN NewsFeed - 24 Nov 2015
Bristol-Myers Squibb Announces U.S. Food and Drug Administration Approval for Opdivo (nivolumab) as a Single Agent for the Treatment of Patients with Previously Untreated BRAF Wild-Type Advanced Melanoma
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 1 Oct 2015
Bristol-Myers Squibb Receives Approval from the U.S. Food and Drug Administration for the Opdivo (nivolumab) + Yervoy (ipilimumab) Regimen in BRAF V600 Wild-Type Unresectable or Metastatic Melanoma
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 24 Apr 2015
Bristol-Myers Squibb Receives Positive CHMP Opinion in the European Union for Opdivo (nivolumab) for the Treatment of Advanced Melanoma in Both First-Line and Previously Treated Patients
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 4 Mar 2015
Bristol-Myers Squibb Signs Exclusive Agreement with Bavarian Nordic for PROSTVAC(R), a Prostate-Specific Antigen-Targeting Cancer Immunotherapy
Biopharmaceuticals Licensing Oncology
 HSMN NewsFeed - 30 Jul 2014
Celldex Therapeutics Announces Senior Leadership Promotions
Biopharmaceuticals Personnel
 HSMN NewsFeed - 27 May 2014
Bristol-Myers Squibb and Incyte Enter Clinical Collaboration Agreement to Evaluate Combination Regimen of Two Novel Immunotherapies
Biopharmaceuticals Oncology
 HSMN NewsFeed - 13 Jan 2014
Merck Initiates Rolling Submission of U.S. Biologics License Application for MK-3475, an Investigational Anti-PD-1 Immunotherapy, in Patients with Advanced Melanoma
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 21 Feb 2013
ARIAD Announces Appointment of European General Manager and Other Key Members of Leadership Team
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 6 Jul 2011
Celldex Expands Senior Management Team with Appointment of Dr. Ronald A. Pepin, Senior Vice President and Chief Business Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 21 Mar 2011
Phase III Study of Investigational Compound Ipilimumab Achieves Primary Endpoint of Improvement in Overall Survival in Previously-Untreated Patients with Metastatic Melanoma
Biopharmaceuticals Oncology
 HSMN NewsFeed - 12 Oct 2010
Dr. Robert Petit Joins Advaxis as V.P. of Clinical Operations
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 18 Aug 2010
Ipilimumab Receives FDA Priority Review Designation for Adult Patients with Previously Treated Advanced Melanoma
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 3 Apr 2008
Medarex Announces Ipilimumab Program Continues to Move Forward
Biopharmaceuticals Oncology
 HSMN NewsFeed - 5 Dec 2007
Bristol-Myers Squibb Company Outlines Strategy and Productivity Transformation Initiative During Update to Investment Community
Biopharmaceuticals
 HSMN NewsFeed - 4 Jan 2007
Medarex Announces Enrollment Complete in Ipilimumab (MDX-010) Monotherapy Pivotal Registrational Trial for Metastatic Melanoma
Biopharmaceuticals Oncology
 HSMN NewsFeed - 7 Dec 2006
Medarex Announces FDA Fast Track Designations for Ipilimumab for the Treatment of Metastatic Melanoma; Fast Track Designations for First-Line Use in Combination With Chemotherapy and Second-Line Use as Monotherapy
Biopharmaceuticals FDA Oncology
 HSMN NewsFeed - 31 Mar 2006
Medarex Announces Initiation of Registrational Trial for Ipilimumab (MDX-010) as Monotherapy in Previously-Treated Metastatic Melanoma Patients
Biopharmaceuticals Oncology
 HSMN NewsFeed - 13 Mar 2006
Cell Genesys to Present Data From Two GVAX(R) Cancer Immunotherapy Clinical Trials at 2006 ASCO Annual Meeting
Biopharmaceuticals Oncology
Return to NewsFeed  
FindReps - Find Great Medical Independent Sales Reps without recruiter fees.
FindReps - available on the Apple App Store for iPhone and iPad.